Oncternal TherapeuticsONCT
ONCT
Delisted
ONCT was delisted on the 3rd of December, 2024.
Financial journalist opinion
Neutral
Seeking Alpha
4 months ago
Oncternal Therapeutics, Inc. (ONCT) Q2 2024 Earnings Call Transcript
Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q2 2024 Earnings Call August 8, 2024 5:00 PM ET Company Participants Richard Vincent - Chief Financial Officer Jim Breitmeyer - President and Chief Executive Officer Salim Yazji - Chief Medical Officer Conference Call Participants Carl Byrnes - Northland Capital Markets Kemp Dolliver - Brookline Capital Markets Operator Greetings and welcome to the Oncternal Therapeutics Second Quarter 2024 Financial Results Call. [Operator Instructions] As a reminder, this conference is being recorded.
Negative
Zacks Investment Research
4 months ago
Oncternal Therapeutics (ONCT) Reports Q2 Loss, Tops Revenue Estimates
Oncternal Therapeutics (ONCT) came out with a quarterly loss of $2.89 per share versus the Zacks Consensus Estimate of a loss of $3.03. This compares to loss of $3 per share a year ago.
Neutral
GlobeNewsWire
4 months ago
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results
SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported second quarter 2024 financial results.
Neutral
GlobeNewsWire
4 months ago
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2024 financial results after the U.S. financial markets close on Thursday, August 8, 2024. Oncternal's management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a business update and discuss the Company's financial results.
Neutral
GlobeNewsWire
5 months ago
Oncternal Therapeutics to Present in JonesTrading Healthcare Summit
SAN DIEGO, July 11, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James Breitmeyer, M.D, Ph.D., Oncternal's President and Chief Executive Officer will present at the JonesTrading Healthcare Seaside Summit being held July 14-16, 2024 in San Diego, California.
Neutral
GlobeNewsWire
6 months ago
Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that enrollment has been completed and dosing initiated for the fifth dose cohort of its Phase 1/2 study of ONCT-534 for the treatment of patients with metastatic castration-resistant prostate cancer who are relapsed or refractory to approved androgen receptor pathway inhibitors (ARPI). Patients in the fifth cohort are receiving ONCT-534, the company's dual-action androgen receptor inhibitor (DAARI), at a dose of 600 mg taken orally once each day. The decision to proceed to this higher dose level was made by the study's Safety Review Committee (SRC) after reviewing data from the fourth dose level of 300 mg ONCT-534 daily. An initial update on ONCT-534 safety and efficacy based on prostate-specific antigen (PSA) levels from this study is expected in the third quarter of 2024 and will include data from this 600 mg dose cohort.
Neutral
Seeking Alpha
7 months ago
Oncternal Therapeutics, Inc. (ONCT) Q1 2024 Earnings Call Transcript
Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q1 2024 Earnings Call Transcript May 9, 2024 5:00 PM ET Company Participants Richard Vincent - CFO Dr. James Breitmeyer - President and CEO Dr. Salim Yazji - Chief Medical Officer Conference Call Participants Carl Byrnes - Northland Capital Markets Hartaj Singh - Oppenheimer Robert Burns - HC Wainwright Kemp Dolliver - Brookline Capital Markets Operator Greetings, welcome to Oncternal's First Quarter 2024 Financial Results Call. At this time, all participants are in a listen-only mode.
Negative
Zacks Investment Research
7 months ago
Oncternal Therapeutics (ONCT) Reports Q1 Loss, Tops Revenue Estimates
Oncternal Therapeutics (ONCT) came out with a quarterly loss of $2.83 per share versus the Zacks Consensus Estimate of a loss of $2.88. This compares to loss of $4 per share a year ago.
Neutral
GlobeNewsWire
7 months ago
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported first quarter 2024 financial results.
Positive
Zacks Investment Research
7 months ago
All You Need to Know About Oncternal Therapeutics (ONCT) Rating Upgrade to Buy
Oncternal Therapeutics (ONCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Charts implemented using Lightweight Charts™